Cubist Systematic Strategies’s Amicus Therapeutics FOLD Stock Holding History

Cubist Systematic Strategies’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$6.79M	Sell	861,451 -1,341,493	-61%	-$9.55M	0.03%	788
2025 Q2	$12.6M	Buy	2,202,944 +1,650,919	+299%	+$10.7M	0.06%	487
2025 Q1	$4.5M	Buy	+552,025	New	+$5.11M	0.03%	942
2024 Q4	–	Sell	-1,083,931	Closed	-$11.6M	–	3168
2024 Q3	$11.6M	Buy	+1,083,931	New	+$11.8M	0.07%	401
2024 Q2	–	Sell	-613,391	Closed	-$7.23M	–	3323
2024 Q1	$7.23M	Buy	613,391 +520,118	+558%	+$6.65M	0.04%	720
2023 Q4	$1.32M	Sell	93,273 -79,035	-46%	-$897K	0.01%	1825
2023 Q3	$2.1M	Buy	172,308 +144,352	+516%	+$1.86M	0.02%	1334
2023 Q2	$351K	Sell	27,956 -215,751	-89%	-$2.56M	﹤0.01%	2565
2023 Q1	$2.7M	Buy	243,707 +172,844	+244%	+$2.13M	0.02%	1427
2022 Q4	$865K	Sell	70,863 -21,113	-23%	-$238K	0.01%	2589
2022 Q3	$960K	Buy	91,976 +70,296	+324%	+$783K	0.01%	2655
2022 Q2	$233K	Buy	21,680 +9,968	+85%	+$82.1K	﹤0.01%	3607
2022 Q1	$111K	Sell	11,712 -131,148	-92%	-$1.23M	﹤0.01%	3212
2021 Q4	$1.65M	Sell	142,860 -205,825	-59%	-$2.29M	0.02%	1540
2021 Q3	$3.33M	Buy	348,685 +163,576	+88%	+$1.67M	0.04%	688
2021 Q2	$1.78M	Sell	185,109 -220,303	-54%	-$2.15M	0.02%	1158
2021 Q1	$4M	Buy	405,412 +311,405	+331%	+$4.82M	0.05%	558
2020 Q4	$2.17M	Sell	94,007 -20,413	-18%	-$417K	0.03%	891
2020 Q3	$1.62M	Buy	114,420 +46,175	+68%	+$673K	0.02%	1037
2020 Q2	$1.03M	Buy	68,245 +45,622	+202%	+$556K	0.02%	1163
2020 Q1	$209K	Sell	22,623 -83,259	-79%	-$791K	0.01%	1710
2019 Q4	$1.03M	Sell	105,882 -233,591	-69%	-$2.14M	0.02%	1138
2019 Q3	$2.72M	Buy	339,473 +304,999	+885%	+$3.31M	0.05%	501
2019 Q2	$430K	Sell	34,474 -244,577	-88%	-$3.1M	0.01%	1583
2019 Q1	$3.79M	Buy	279,051 +270,293	+3,086%	+$3.3M	0.12%	211
2018 Q4	$84K	Sell	8,758 -3,432	-28%	-$37.7K	﹤0.01%	1791
2018 Q3	$147K	Buy	12,190 +7,953	+188%	+$111K	0.01%	1504
2018 Q2	$66K	Buy	+4,237	New	+$64.1K	﹤0.01%	1609
2018 Q1	–	Sell	-2,500	Closed	-$36K	–	1911
2017 Q4	$36K	Sell	2,500 -12,800	-84%	-$176K	﹤0.01%	1800
2017 Q3	$231K	Buy	+15,300	New	+$202K	0.01%	1350
2017 Q2	–	Sell	-6,386	Closed	-$46K	–	1741
2017 Q1	$46K	Buy	6,386 +6,246	+4,461%	+$39.5K	﹤0.01%	1482
2016 Q4	$1K	Sell	140 -11,795	-99%	-$81.6K	﹤0.01%	1683
2016 Q3	$88K	Sell	11,935 -4,652	-28%	-$31.4K	0.01%	1494
2016 Q2	$91K	Buy	+16,587	New	+$116K	0.01%	1524
2016 Q1	–	Sell	-31,008	Closed	-$301K	–	1685
2015 Q4	$301K	Sell	31,008 -23,161	-43%	-$209K	0.02%	1113
2015 Q3	$758K	Buy	+54,169	New	+$850K	0.04%	715
2015 Q2	–	Sell	-7,687	Closed	-$84K	–	1883
2015 Q1	$84K	Buy	+7,687	New	+$67.8K	﹤0.01%	1694
2014 Q4	–	Sell	-28,622	Closed	-$170K	–	1943
2014 Q3	$170K	Buy	+28,622	New	+$150K	0.01%	1429

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Cubist Systematic Strategies's FOLD Position: Q3 2025 in Review

Cubist Systematic Strategies reduced its Amicus Therapeutics (FOLD) stake by 61% in Q3 2025, selling an estimated $9.55M and leaving 861,451 shares worth $6.79M. The position accounts for 0.03% of the portfolio, ranked #788.

Cubist Systematic Strategies first reported a position in FOLD in Q3 2014 and has held it in 38 quarters since. The position peaked at $12.6M in Q2 2025. 287 funds tracked by Wall St. Rank hold FOLD as of Q3 2025.

Cubist Systematic Strategies held 861,451 shares of Amicus Therapeutics worth $6.79M as of Q3 2025.
Cubist Systematic Strategies sold 1,341,493 Amicus Therapeutics shares in Q3 2025, an estimated $9.55M.
Amicus Therapeutics made up 0.03% of Cubist Systematic Strategies's portfolio in Q3 2025, its #788 holding.
Cubist Systematic Strategies first reported a position in Amicus Therapeutics in Q3 2014 and has held it in 38 quarters since.
Cubist Systematic Strategies's Amicus Therapeutics position peaked at $12.6M in Q2 2025.
287 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.